At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
Observationalother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exploratory Investigation of Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
In Brief
An observational study evaluating Observational for Eosinophilic Asthma. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to identify differentially expressed gene transcripts after initiation of mepolizumab in individuals with severe eosinophilic asthma (SEA).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEosinophilic Asthma
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartFeb 2021
First PostedAug 2021
Primary CompletionFeb 2023
Study CompletionDec 2025
TodayJul 2026
First PostedAug 12, 2021
Enrollment StartFeb 16, 2021
Primary CompletionFeb 13, 2023
Study CompletionDec 11, 2025
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 4.9 years ago
Interventions
Observationalother
Enrolled patients had a prescription for mepolizumab provided during the course of routine clinical care, and enrollment occurred prior to the initiation of mepolizumab.